Compare · A vs RVTY
A vs RVTY
Side-by-side comparison of Agilent Technologies Inc. (A) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $32.65B, about 3.4x RVTY ($9.68B).
- Over the past year, A is up 8.6% and RVTY is down 6.8% - A leads by 15.4 points.
- RVTY has been more active in the news (6 items in the past 4 weeks vs 4 for A).
- A has more recent analyst coverage (25 ratings vs 18 for RVTY).
- Company
- Agilent Technologies Inc.
- Revvity Inc.
- Price
- $115.55+3.85%
- $86.67+5.21%
- Market cap
- $32.65B
- $9.68B
- 1M return
- +1.43%
- -1.16%
- 1Y return
- +8.61%
- -6.77%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1999
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 18
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Bloomberg Expands Global Equity Offering with Australia Domestic Equity Indices
- Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
- Agilent Showcases Cancer Research Solutions at AACR 2026
- Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits
- Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Henson Meghan
- Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
- Amendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
- SEC Form 4 filed by Rataj Sue H.
Latest RVTY
- Revvity Board Declares Quarterly Dividend
- SEC Form 4 filed by Gonzales Anita
- Revvity to Present at Upcoming Investor Conferences
- Revvity downgraded by Barclays with a new price target
- Revvity to Hold Earnings Call on Tuesday, May 5, 2026
- Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
- SEC Form 4 filed by Gonzales Anita
- SEC Form DEFA14A filed by Revvity Inc.
- SEC Form DEF 14A filed by Revvity Inc.
- Officer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)